Lung Cancer
Beamion LUNG-2: A Phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered zongertinib (BI 1810631) compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations (1479-0008)
- Details
ClinicalTrials.gov ID:
NCT06151574
Diagnosis Type:
NA
USOR Number:
- Address
,
P: